Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125919791 | 12591979 | 1 | I | 20160314 | 20160315 | 20160726 | 20160726 | PER | US-UNITED THERAPEUTICS-UNT-2016-004355 | UNITED THERAPEUTICS | 62.24 | YR | F | Y | 57.69000 | KG | 20160726 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125919791 | 12591979 | 1 | PS | ORENITRAM | TREPROSTINIL | 1 | Oral | 0.125 MG, TID | N | 2100684 | 203496 | .125 | MG | TABLET | TID | ||||
| 125919791 | 12591979 | 2 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | 5.75MG, BID | N | 203496 | 5.75 | MG | TABLET | BID | |||||
| 125919791 | 12591979 | 3 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | 5.5MG, BID | N | 203496 | 5.5 | MG | TABLET | BID | |||||
| 125919791 | 12591979 | 4 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | 0.25 MG, Q8H WITH FOOD | N | 2100476 | 203496 | .25 | MG | TABLET | TID | ||||
| 125919791 | 12591979 | 5 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | 0.125 MG, TID | N | 2100476 | 203496 | .125 | MG | TABLET | TID | ||||
| 125919791 | 12591979 | 6 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | 0.25 MG, TID | N | 2100476 | 203496 | .25 | MG | TABLET | TID | ||||
| 125919791 | 12591979 | 7 | SS | ORENITRAM | TREPROSTINIL | 1 | Oral | UNK | N | 2100684 | 203496 | TABLET | |||||||
| 125919791 | 12591979 | 8 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Oral | 5 MG,QD | 0 | 5 | MG | TABLET | QD | ||||||
| 125919791 | 12591979 | 9 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Oral | 5MG,BID | 0 | 5 | MG | TABLET | BID | ||||||
| 125919791 | 12591979 | 10 | SS | GLIPIZIDE. | GLIPIZIDE | 1 | Unknown | U | U | 0 | |||||||||
| 125919791 | 12591979 | 11 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 125919791 | 12591979 | 12 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 125919791 | 12591979 | 13 | C | LANTUS | INSULIN GLARGINE | 1 | 0 | ||||||||||||
| 125919791 | 12591979 | 14 | C | TRAMADOL. | TRAMADOL | 1 | Unknown | 0 | |||||||||||
| 125919791 | 12591979 | 15 | C | XIFAXAN | RIFAXIMIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125919791 | 12591979 | 1 | Pulmonary hypertension |
| 125919791 | 12591979 | 8 | Pulmonary hypertension |
| 125919791 | 12591979 | 10 | Diabetes mellitus |
| 125919791 | 12591979 | 11 | Diabetes mellitus |
| 125919791 | 12591979 | 12 | Product used for unknown indication |
| 125919791 | 12591979 | 13 | Product used for unknown indication |
| 125919791 | 12591979 | 14 | Product used for unknown indication |
| 125919791 | 12591979 | 15 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125919791 | 12591979 | Blood magnesium decreased | |
| 125919791 | 12591979 | Diarrhoea | |
| 125919791 | 12591979 | Dizziness | |
| 125919791 | 12591979 | Headache |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125919791 | 12591979 | 1 | 20160111 | 201603 | 0 | |
| 125919791 | 12591979 | 8 | 20110813 | 0 |